The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid.
 
David Berz
Employment - Valkyrie Clinical Trials
Leadership - Jazz Pharmaceuticals; Sun Pharma
Honoraria - EMD Serono; Sun Pharma
Research Funding - Ascendis Pharma; BeiGene; BioNTech; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; eFFECTOR Therapeutics; Faeth Therapeutics; G1 Therapeutics; Genprex; Hongyun Biotech; Incyte; InhibRx; Mirati Therapeutics; Seagen; Summit Therapeutics; WhiteOak; Xencor
Travel, Accommodations, Expenses - EMD Serono; Jazz Pharmaceuticals
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb/Medarex; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genprex (Inst); Hybercell (Inst); ImmunityBio (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Nextcure (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Tubulis GmbH (Inst)
Patents, Royalties, Other Intellectual Property - Genprex
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; Natera; OSE Immunotherapeutics; Pfizer; Rigel; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
Travel, Accommodations, Expenses - Hotspot Therapeutics
 
Thomas Atkinson
Employment - Ochsner Health System
 
Robert Jotte
Leadership - Sarah Cannon Research Institute
 
Kartik Konduri
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi Sankyo; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Pfizer; Regeneron; squibb
 
Donald Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Mark Berger
Employment - Genprex
Leadership - Genprex
Stock and Other Ownership Interests - Genprex
Patents, Royalties, Other Intellectual Property - Am holder of patents at Genprex Inc. that do not provide for any payments to me